Regulatory Strategy & Guidance

Regulatory Strategy and Guidance

Focused, evidence-based regulatory strategy from consultants who know the FDA, TGA and EMA frameworks from the inside.

Accelerate Your Drug Development Journey with a Clear Regulatory Roadmap

Trans-Pacific Compliance provides tailored regulatory strategies that align with your product goals, development timeline and target markets. Our senior consultants draw on deep FDA and TGA expertise to guide you from concept through to approval — reducing risk, avoiding costly detours and getting your product to market faster.

Whether you are at pre-clinical stage or approaching a marketing application, we build the regulatory pathway around your specific product, data and commercial objectives.

Professionals planning strategy together at laptops

Tailored Regulatory Strategies

Every product has a different regulatory profile. We assess your compound or device, your clinical data and your target markets to define the most efficient approval pathway — avoiding common pitfalls and building a strategy that holds up under agency scrutiny.

Our strategies cover FDA, TGA, EMA and key Asian markets, with options to coordinate multi-jurisdictional submissions where appropriate.

Application type selection (NDA, ANDA, 505(b)(2), BLA, 510(k), PMA)
Multi-jurisdictional pathway planning
Target product profile development
Regulatory gap analysis and risk mapping
Pre-clinical and clinical study design guidance

Professional team discussing a regulatory briefing

Expert FDA and TGA Consultation

Our consultants provide direct, actionable advice on regulatory decisions — from initial product classification through complex lifecycle changes. Every engagement is led by a senior consultant, not delegated to junior staff.

We help you make informed decisions quickly, drawing on current agency expectations and a track record of successful submissions across therapeutic categories.

Senior-led advisory engagements
FDA pre-submission meeting preparation
TGA pre-application consultation
Regulatory opinion letters and memos
Development programme review and critique

Medical specialist reviewing information in a clinical facility

Risk Assessment and Mitigation

Regulatory risk is best identified early — before it becomes a delay or a rejection. We conduct structured risk assessments at key development milestones to surface issues, quantify their impact and put mitigation plans in place before they affect your timeline.

Our risk assessments are practical and decision-focused. The output is a clear action plan your team can execute.

Regulatory risk identification at key milestones
CMC, clinical and labeling risk review
Agency interaction risk management
Contingency planning for likely agency questions
Post-approval risk monitoring

Who this is for

Pharmaceutical, biotech, generic and medical device companies at any stage of development — from first-in-class products entering pre-IND through to marketed products seeking new indications.

Get in touch

Tell us about your product and target market. We will outline the regulatory pathway and identify the key risks in one consultation.

Book a free consultation +1 706-773-4965

Work with us

Ready to move your product forward?

A free 30-minute consultation with one of our senior regulators costs nothing and can save months of misdirected effort.

Free Consultation